Granules India Reports Q2 Revenue Growth Amid USFDA Inspection Observations
Granules India reported a 20% revenue increase to Rs 1,560 crore in Q2 FY27, with net profit rising 39% to Rs 181.8 crore. EBITDA grew 21%, and net cash reached Rs 828 crore, improving from net debt last quarter. The company’s revenue mainly came from North America and Europe, with finished dosages as the largest segment. A recent USFDA inspection at its Hyderabad facility resulted in 11 observations, which the company said will be addressed through corrective actions without impacting production or distribution.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (60/100). Lens Score 36/100.
Outlets measured: freepressjournal, moneycontrol. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (52–68/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
moneycontrol broke this story on 2 Nov, 02:13 am. Other outlets followed.